Citigroup initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $40.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
| 11/29/2023 | $32.00 | Outperform → In-line | Evercore ISI |
| 10/5/2023 | Peer Perform | Wolfe Research |
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
10-Q - Carlyle Group Inc. (0001527166) (Filer)
N-PX - Carlyle Group Inc. (0001527166) (Filer)
4 - Carlyle Group Inc. (0001527166) (Reporting)
4 - Carlyle Group Inc. (0001527166) (Issuer)
4 - Carlyle Group Inc. (0001527166) (Issuer)
SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, February 26, 2025 to announce its financial results for the fourth quarter and full year ended December 31, 2024. A news release containing the quarterly results will be issued on Tuesday, February 25, 2025. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CG
Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that it has entered into a definitive agreement to acquire Forgital Group ("Forgital" or the "Company"), a leading manufacturer of advanced forged and machine-finished components for aerospace and industrial end markets, from global investment firm Carlyle (NASDAQ:CG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241215926348/en/ Forgital, founded in 1873, specializes in forged and laminated metallic rolled rings, with technologically advanced manufacturing capabilities across a broad portfolio of materials, includi
MCLEAN, Va., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced that its Independent Medical Expert Consulting Services (IMEDECS) division has earned URAC accreditation as an Independent Review Organization (IRO), marking 24 years of full accreditation. This latest accreditation, for the 6.0: Comprehensive Review standards, demonstrates that IMEDECS has the policies, procedures, and structure needed to deliver fair and impartial peer-reviewed medical determinations that help its clients improve health
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, February 26, 2025 to announce its financial results for the fourth quarter and full year ended December 31, 2024. A news release containing the quarterly results will be issued on Tuesday, February 25, 2025. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CG
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its third quarter ended September 30, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "We delivered consistent performance in the third quarter of 2024, capitalizing on increased new deal activity and the strength of our existing portfolio companies. With another strong quarter of originations, we benefited from access to the broader Carlyle Global Credit Platform, as we supplemented our core cash flow strategy with differentiated deal flow and specialty lending
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
MCLEAN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology solutions and clinical services company dedicated to helping government healthcare agencies accelerate better health outcomes, has named Brett Barton as Senior Vice President (SVP) of Client Experience. In this newly created role, Barton will represent the voice of the client across multiple touchpoints to deliver an exceptional experience that supports continued growth for the company and elevates the Acentra Health brand. Barton brings over three decades of experience in healthcare technology and services supporting the public sector and health and human services market. He comes to Acentra Health from Gainwell
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00
Redburn Atlantic initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $55.00